| 摘要 |
FIELD: biotechnologies.SUBSTANCE: invention proposes a humanised monoclonal antibody or its fragment including variable regions of light and heavy chains obtained from a mouse monoclonal antibody mBAT-1 in a combination with at least one chemotherapeutic agent based on platinum, antimetabolites or paclitaxel for treatment of a tumour disease. The invention describes use of a humanised monoclonal antibody or its fragment including variable regions of easy and heavy chains obtained from a mouse monoclonal antibody mBAT-1, in a combination with at least one chemotherapeutic agent based on platinum, antimetabolites or paclitaxel to improve survivability of an individual with tumour, who is treated at least with one chemotherapeutic agent.EFFECT: synergetic effect expressed in increase of survivability of lymphocytes or decrease of tumour volume in comparison to use of h-BAT, which can be used in medicine for tumour treatment.11 cl, 20 dwg, 2 tbl, 8 ex |
